About
Camereyes has developed a simple end-to-end solution for detecting and monitoring diabetic retinopathy. The company's InSight leverages optics and deep-learning algorithms to provide a low-cost, fully automated solution in areas where professional eye care specialists may be scarce. InSight requires no special setup or skills, making it suitable for remote locations. Patients do not require pupil dilation; instead, they simply slip on a headset, and with the press of a button, high-quality fundus images are automatically captured and sent for storage in the cloud. Camereyes uses a network of professional reading centers with accredited graders supported by machine-learning algorithms to analyze the images and generate detailed reports, which are sent back within minutes to the point of care.
Funding history · 2 rounds · $950K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Camereyes' primary focus?
- Camereyes developed an end-to-end solution for detecting and monitoring diabetic retinopathy, leveraging optics and deep-learning algorithms.
- When was Camereyes founded?
- Camereyes was founded in February 2015.
- What is the operational status of Camereyes?
- Camereyes is currently inactive, having ceased operations in January 2020.
- Where is Camereyes headquartered?
- Camereyes is headquartered in Jerusalem, Israel.
- What is the name of Camereyes' core product?
- Camereyes' core product is called InSight.
- How much total funding did Camereyes raise?
- Camereyes raised a total of $950,000 in funding. For a full financing history, please refer to startupim.
- Which investor participated in Camereyes' funding rounds?
- VLX Ventures invested in Camereyes' seed funding rounds.
- When was Camereyes' last known funding round?
- Camereyes' last known funding round was a Seed round in April 2018, raising $300,000.
- What is the estimated employee count for Camereyes?
- Camereyes had an estimated employee count in the range of 1-10 people.